-Data demonstrates durable responses across 3 cohorts of patients with recurrent and newly diagnosed GBM- -Data supports continued clinical development of ST101 as a backbone treatment in combination with standard-of-care and immune-oncology agents- TARRYTOWN, N.Y., June 1, 2024…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.